Micron receives Phase 1 SBIR contract from CDC

ATLANTA, September 6, 2016 – The Centers for Disease Control and Prevention (CDC) awards Micron Biomedical, Inc. a Phase 1 SBIR contract for the development of a microneedle patch for delivery of a proprietary inactivated rotavirus vaccine (IRV) developed by the CDC to overcome safety and efficacy issues associated with currently-licensed oral rotavirus vaccines in children.  Under the terms of the contract, Micron will develop a formulation to stabilize the IRV, develop patches that contain a full human dose of IRV, design a scalable manufacturing process for the IRV microneedle patch, and use that process to manufacture IRV microneedle patches to support pre-clinical studies.